Highlights Of The Program
2 days business program:
Learn from real-world case studies by industry leaders.
SHOWCASING INNOVATION:
Discover the latest technology and techniques from across the industry.
leaders talk:
Hear from top-level experts about how to stay ahead in a fast-changing industry.
MULTIPLE STREAMS:
A business program that is multi-disciplinary, giving you a broad view of the industry.
SMART TECHNOLOGIES:
Explore the latest smart and AI-driven solutions, and see how they can be used in your business.
roundtable discussion:
Join talks with industry peers. Share ideas, make connections, and find new partners.
Program 2026
DAY 1 :
WEDNESDAY, 22 JULY, 2026
08:00 - 08:50
REGISTRATION AND MORNING REFRESHMENTS
08:50 - 09:00
OPENING ADDRESS
09:00 - 09:25
ESTABLISHING AN “RNA COOPERATIVE” TO CO-DEVELOP AN mRNA VACCINE
Jens Demand
PATH
- Empowering LMIC manufacturers with hands-on RNA vaccine expertise and shared resources
- Pooling members across regions to co-develop candidates and strengthen RNA vaccine portfolios
- Mentoring teams towards Phase 1 readiness through collaborative tech transfer and trial planning
09:25 - 09:30
Q&A SESSION ON PATH’S RNA COOPERATIVE FOR mRNA VACCINE CO-DEVELOPMENT
09:30 - 09:55
NOVEL APPROACH TO IDENTIFY BIOMARKERS FOR mRNA-BASED THERAPEUTICS AND VACCINES
Fredrik Sundberg
Illumina
- Spotlighting market trends and biomarker gaps for safer, more effective mRNA modalities
- Correlating richer biological data with stratification decisions and clinical outcome signals
- Extracting autoantibody biomarker insights from post-COVID and vaccine case studies
09:55 - 10:00
Q&A SESSION ON BIOMARKERS FOR mRNA THERAPEUTICS AND VACCINES
10:00 - 10:30
SPEED NETWORKING SESSION
- Exchange business cards and get connected in short one-to-one meetings
- Start the conversation to arrange a more formal meeting later on in the conference
- Share your professional background and discuss your biggest business issues – don't forget your business cards!
10:30 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
SPONSORED BY COJOURNEY
11:00 - 11:30
PANEL DISCUSSION ON HARNESSING DATA FOR THE DEVELOPMENT OF SAFE AND RELIABLE RNA THERAPEUTICS
- Pinpointing where analytical measurement lags formulation progress and which mRNA-LNP manufacturing stage remains the weakest data link
- Harmonising analytical, stability and potency data for reliable comparability across manufacturing changes, platforms and suppliers
- Strengthening AI models for RNA therapeutics against small, heterogeneous datasets biased towards successful formulations
- Charting the data strategy from emergency authorisation to full licensure and platform-level regulatory approval
Albert Grau | Marama Labs
Manuel Alfaro | National Institute for Bioprocessing Research & Training
Felix Sieber-Schäfer | LMU München
Sarah Arden | Cambase Life Sciences
11:30 - 11:55
ENABLING RAPID mRNA VACCINE DEVELOPMENT WITH CELL-FREE DNA TEMPLATES FOR PANDEMIC PREPAREDNESS
Anusha Dias
Sanofi
- Replacing plasmids with cell-free DNA to speed IVT template supply without endotoxin risks
- Leveraging rolling circle amplification to yield long linear constructs with high sequence fidelity
- Integrating enzymatic digestion and mRNA characterisation to cut timelines and improve flexibility
11:55 - 12:00
Q&A SESSION ON cfDNA TEMPLATES FOR RAPID mRNA VACCINES
12:00 - 12:25
MRNA SEQUENCE DESIGN AND mRNA-BASED IN VIVO CAR-T THERAPEUTICS
Zhongyao Ma
WuXi AppTec
- Designing combinatorial LNP libraries and screening candidates for in vivo delivery performance
- Refining mRNA sequences and UTRs to improve expression, stability, and activity
- Demonstrating in vivo CAR-T generation using mRNA-tLNPs through a focused case-study programme
12:25 - 12:30
Q&A SESSION ON mRNA DESIGN FOR IN VIVO CAR-T THERAPEUTICS
12:30 - 13:30
NETWORKING LUNCH AND VISITING THE mRNA CONFERENCE EXHIBITION
13:30 - 13:55
NEXT-GENERATION RNA MEDICINES FOR LOWER-COST, HIGHER-QUALITY IN VIVO CANCER THERAPEUTICS AND VIRAL VACCINES
Parker Moss
Wellcome Leap
- Scaling distributed RNA biofoundries to replace slow, costly biologics with rapid RNA output
- Automating codon optimisation and continuous-flow RNA manufacturing to boost expression and fidelity
- Encoding CAR-T BiTEs and personalised vaccines to cut costs and speed translation to scale
13:55 - 14:00
Q&A SESSION ON LOWER-COST IN VIVO RNA CANCER THERAPIES
14:00 - 14:25
AI-DRIVEN DESIGN AND IMMUNOPEPTIDOMIC CHARACTERISATION OF mRNA VACCINE CANDIDATES
Alexandru Odainic
NEC Bio
- Harnessing AI-based antigen ordering to guide computational mRNA vaccine candidate design
- Mapping peptide presentation landscapes following mRNA vaccine transfection via immunopeptidomics
- Bridging computational and experimental methods to accelerate multipayload mRNA construct design
14:25 - 14:30
Q&A SESSION ON AI AND IMMUNOPEPTIDOMICS IN mRNA VACCINE DISCOVERY
14:30 - 14:55
ADVANCING RNA THERAPEUTICS WITH SENS™ POLYMER–LIPID HYBRID NANOPARTICLES
Sunny Song
Samyang Biopharm
- Deploying SENS™ hybrid nanoparticles for tissue-selective RNA therapeutic delivery
- Engineering biodegradable polymer and ionisable lipid cores to balance potency and safety
- Targeting spleen, lung, muscle, CNS, and liver while supporting repeat dosing profiles
14:55 - 15:00
Q&A SESSION ON HYBRID NANOPARTICLES FOR RNA DELIVERY
15:00 - 15:20
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:20 - 15:45
FROM PLASMID TO PATIENT: GMP CONSIDERATIONS AND CMC STRATEGIES FOR mRNA SCALE-UP
Lijun Wang
CoJourney
- Orchestrating GMP tech transfer and scale-up to streamline mRNA production readiness
- Standardising pDNA design and supply to strengthen CMC success for mRNA therapeutics
- De-risking COGS and manufacturing strategy by aligning plasmid processes with scale goals
15:45 - 15:50
Q&A SESSION ON GMP AND CMC STRATEGIES FOR mRNA SCALE-UP
15:50 - 16:15
THERAPEUTIC NUCLEIC ACIDS – ADVANCED SOLUTIONS FOR DOWNSTREAM PROCESSING AND ANALYTICS
Carsten Arlt
Tosoh Bioscience GmbH
- Calibrating chromatographic methods tailored for high-purity therapeutic oligonucleotides
- Purifying across impurity classes from shortmers and longmers to process-related contaminants
- Reviewing case studies to guide strategy selection and optimisation for robust downstream workflows
16:15 - 16:20
Q&A SESSION ON OLIGO DOWNSTREAM PROCESSING AND ANALYTICS
16:20 - 16:45
NOVEL RIG-I AGONIST–ADJUVANT FOR TUNABLE INNATE IMMUNE STIMULATION BY mRNA VACCINES
Svenja Dudek
University Hospital Bonn
- Minimizing dsRNA byproducts by tuning IVT templates and coding composition for clean mRNA
- Hybridising RIG-I ligands to the mRNA 3'-UTR to deliver controllable innate co-stimulation
- Balancing translation with type I IFN signalling to boost T- and B-cell responses
- Lowering purification requirements to avoid inflammatory side effects of dsRNA by-products
16:45 - 16:50
Q&A SESSION ON TUNABLE RIG-I ADJUVANT FOR mRNA VACCINES
16:50 - 17:15
NON-LNP mRNA DELIVERY TO IMMUNE CELLS: A PEPTIDE PLATFORM APPROACH FOR CANCER IMMUNOTHERAPY
Kaido Kurrikoff
Vectiopep
- Pinpointing LNP liver tropism as the barrier that leaves immune-cell-selective mRNA cancer vaccines unaddressed
- Delivering over 99% immune-cell selectivity and under 0.4% liver uptake with a peptide carrier
- Driving 10× stronger antigen-specific T-cell activation than LNP benchmarks in preclinical models
- Mapping the platform's reach from MSS colorectal cancer to a broader class of therapeutic and prophylactic mRNA vaccines
17:15 - 17:20
Q&A SESSION ON SELECTIVE mRNA DELIVERY TO IMMUNE CELLS
17:20 - 18:20
NETWORKING DRINKS RECEPTION
DAY 2 :
THURSDAY, 23 JULY, 2026
08:00 - 08:30
MORNING REFRESHMENTS
08:30 - 08:40
OPENING ADDRESS
08:40 - 09:05
THE CENTRAL ROLE OF RNA TECHNOLOGY IN CEPI'S STRATEGY FOR RAPID, SCALABLE, AND EQUITABLE VACCINE DEVELOPMENT
Martina Ochs
Coalition for Epidemic Preparedness Innovations (CEPI)
- Mobilising CEPI's 100 Days Mission to ready a new vaccine within 100 days of a pandemic threat
- Positioning RNA vaccine platforms as the central enabler of rapid, scalable outbreak response
- Funding RNA technology, including innovations in speed, thermostability, manufacturability, durability, and delivery
09:05 - 09:10
Q&A SESSION ON RNA TECHNOLOGY FOR RAPID PANDEMIC VACCINE RESPONSE
09:10 - 09:35
PATENT STRATEGY FOR RNA THERAPEUTICS IN EUROPE AND THE US
Ross Cummings
Gill Jennings & Every LLP
- Clarifying EU and US patent eligibility boundaries for RNA sequences and modification
- Structuring claim strategies across RNA types, using sequence plus chemistry combinations
- Evidencing inventions with the right experimental data, knowing when and what to show
09:35 - 09:40
Q&A SESSION ON PATENT STRATEGY FOR RNA THERAPEUTICS
09:40 - 10:05
INTRANASAL mRNA VACCINE: TARGETING THE FRONT LINES OF RESPIRATORY VIRUS DEFENCE
Sudha Chivukula
Sanofi
- Protecting airways by inducing mucosal immunity where respiratory viruses first replicate
- Eliciting robust pulmonary immune responses through intranasal dosing rather than traditional injections
- Reducing influenza and RSV viral loads across species to help stop infection at the source
10:05 - 10:10
Q&A SESSION ON INTRANASAL mRNA VACCINES
10:10 - 10:30
MORNING COFFEE BREAK IN THE EXHIBIT AREA
SPONSORED BY NOF EUROPE GmbH
10:30 - 10:55
EUROPEAN PATENTS – THE UNIFIED PATENT COURT, OPPOSITIONS AND MORE
Thomas Ricketts
Boult Wade Tennant LLP
- Explaining how the Unified Patent Court has evolved since its launch and early case learnings
- Comparing opt-out choices and Unitary Patents for securing broad protection across Europe
- Navigating validity and infringement routes across EPO, UPC, and national courts in key markets
10:55 - 11:00
Q&A SESSION ON UPC STRATEGY AND EUROPEAN PATENT ENFORCEMENT
11:00 - 11:25
ADVANCING mRNA IVT PERFORMANCE: HiXCap™ CAP ANALOGUES AND ENGINEERED T7 POLYMERASE
Lena Preuss
Hongene Biotech Germany GmbH
- Overcoming IFIT1-driven mRNA suppression to enable translation under immune activation conditions
- Documenting HiXCap™ E2 efficacy across in vitro and in vivo models towards clinical-stage readiness
- Boosting IVT mRNA yield and curbing dsRNA impurities through engineered T7 RNA polymerase
11:25 - 11:30
Q&A SESSION ON CAP ANALOGUE AND T7 ENGINEERING FOR CLEANER HIGH-YIELD mRNA
11:30 - 11:55
ONE ASSAY TO RULE THEM ALL: REPLACING MULTI-METHOD mRNA QC WITH A SINGLE NANOPORE WORKFLOW
Michael Hanson
Oxford Nanopore Technologies
- Streamlining mRNA QC by replacing CE, HPLC, and gels with a single nanopore workflow
- Consolidating identity, integrity, capping, poly-A tail, and dsRNA metrics in one run
- Justifying GMP adoption with cost comparisons and regulatory defensibility for batch release
11:55 - 12:00
Q&A SESSION ON A SINGLE NANOPORE WORKFLOW FOR mRNA QC
12:00 - 12:30
RESERVED PRESENTATION
12:30 - 13:30
NETWORKING LUNCH & VISIT THE MRNA CONFERENCE EXHIBITION
13:30 - 13:55
ACCELERATING mRNA THERAPEUTIC DEVELOPMENT AND OPTIMISATION THROUGH PREDICTIVE MECHANISTIC MODELLING
Luca Marchetti
Centre for Computational and Systems Biology (COSBI)
- Predicting development outcomes with mechanism-driven models that speed mRNA translation to the clinic
- Guiding candidate selection and translation plans across delivery routes and therapeutic modalities
- Adjusting dosing schedules and product design to shorten timelines and raise clinical success odds
13:55 - 14:00
Q&A SESSION ON PREDICTIVE MECHANISTIC MODELING FOR mRNA THERAPEUTICS
14:00 - 14:25
MECHANISM AND PREVENTION OF SYSTEMIC INFLAMMATION CAUSED BY mRNA VACCINES
János Szebeni
Semmelweis University
- Unpacking rare inflammatory organ-level events seen after mRNA LNP vaccination, including myopericarditis
- Modelling off-target LNP distribution that drives multiorgan spike expression and autoimmune injury
- Preventing adverse events using porcine in vivo studies to test mitigation strategies for safer dosing
14:25 - 14:30
Q&A SESSION ON PREVENTING INFLAMMATION AFTER mRNA VACCINES
14:30 - 15:00
RESERVED PRESENTATION
15:00 - 15:15
FEEDBACK AND RAFFLE DRAW
15:15 - 15:30
CLOSING REMARKS
Become a Speaker & Join the Conversation
SUBSCRIBE FOR UPDATES
By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.